Preliminary Analysis of Potentially Overlapping Differentially Expressed Proteins in Both the Spinal Cord and Brain of SOD1 G93A Mice

Overview

Journal Curr Protein Pept Sci

Publisher Bentham Science Publishers

Specialty Biochemistry

Date 2024 Jul 10

PMID 38984582

Authors

Shi-Shi Jiang

Shishi Jiang

Hong-Bing Nie

Hongbing Nie

Shan Hua

Meng Xie

Renshi Xu

Ren-Shi Xu

Affiliations

Soon will be listed here.

Abstract

Objective: Proteomic elucidation is an essential step in improving our understanding of the biological properties of proteins in amyotrophic lateral sclerosis (ALS).

Methods: Preliminary proteomic analysis was performed on the spinal cord and brain of SOD1 G93A (TG) and wild-type (WT) mice using isobaric tags for relative and absolute quantitation.

Results: Partial up- and downregulated proteins showing significant differences between TG and WT mice were identified, of which 105 proteins overlapped with differentially expressed proteins in both the spinal cord and brain of progression mice. Bioinformatic analyses using Gene Ontology, a cluster of orthologous groups, and Kyoto Encyclopedia of Genes and Genomes pathway revealed that the significantly up- and downregulated proteins represented multiple biological functions closely related to ALS, with 105 overlapping differentially expressed proteins in the spinal cord and brain at the progression stage of TG mice closely related to 122 pathways. Differentially expressed proteins involved in a set of molecular functions play essential roles in maintaining neural cell survival.

Conclusion: This study provides additional proteomic profiles of TG mice, including potential overlapping proteins in both the spinal cord and brain that participate in pathogenesis, as well as novel insights into the up- and downregulation of proteins involved in the pathogenesis of ALS.

References

Xu R, Yuan M . Considerations on the concept, definition, and diagnosis of amyotrophic lateral sclerosis. Neural Regen Res. 2021; 16(9):1723-1729. PMC: 8328770. DOI: 10.4103/1673-5374.306065. View

Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F . Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020; 94(17):e1835-e1844. PMC: 7274849. DOI: 10.1212/WNL.0000000000009322. View

Cruz M . Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. P T. 2018; 43(1):25-28. PMC: 5737249. View

Libro R, Bramanti P, Mazzon E . The role of the Wnt canonical signaling in neurodegenerative diseases. Life Sci. 2016; 158:78-88. DOI: 10.1016/j.lfs.2016.06.024. View

Rozas P, Bargsted L, Martinez F, Hetz C, Medinas D . The ER proteostasis network in ALS: Determining the differential motoneuron vulnerability. Neurosci Lett. 2016; 636:9-15. DOI: 10.1016/j.neulet.2016.04.066. View

Bozzo F, Mirra A, Carri M . Oxidative stress and mitochondrial damage in the pathogenesis of ALS: New perspectives. Neurosci Lett. 2016; 636:3-8. DOI: 10.1016/j.neulet.2016.04.065. View

Chi S, Jiang T, Tan L, Yu J . Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy. Neurosci Biobehav Rev. 2016; 66:127-42. DOI: 10.1016/j.neubiorev.2016.03.033. View

Tokuda E, Furukawa Y . Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations. Int J Mol Sci. 2016; 17(5). PMC: 4881462. DOI: 10.3390/ijms17050636. View

Lacorte E, Ferrigno L, Leoncini E, Corbo M, Boccia S, Vanacore N . Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: A systematic review. Neurosci Biobehav Rev. 2016; 66:61-79. DOI: 10.1016/j.neubiorev.2016.04.007. View

10.

Bozzoni V, Pansarasa O, Diamanti L, Nosari G, Cereda C, Ceroni M . Amyotrophic lateral sclerosis and environmental factors. Funct Neurol. 2016; 31(1):7-19. PMC: 4819821. DOI: 10.11138/fneur/2016.31.1.007. View

11.

Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A . Recent advances in amyotrophic lateral sclerosis. J Neurol. 2016; 263(6):1241-54. PMC: 4893385. DOI: 10.1007/s00415-016-8091-6. View

12.

Browne E, Abbott B . Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. Eur J Med Chem. 2016; 121:918-925. DOI: 10.1016/j.ejmech.2016.02.048. View

13.

Edens B, Miller N, Ma Y . Impaired Autophagy and Defective Mitochondrial Function: Converging Paths on the Road to Motor Neuron Degeneration. Front Cell Neurosci. 2016; 10:44. PMC: 4776126. DOI: 10.3389/fncel.2016.00044. View

14.

Leis A, Ross M, Verheijde J, Leis J . Immunoablation and Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: The Ultimate Test for the Autoimmune Pathogenesis Hypothesis. Front Neurol. 2016; 7:12. PMC: 4749695. DOI: 10.3389/fneur.2016.00012. View

15.

Komine O, Yamanaka K . Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015; 77(4):537-49. PMC: 4664586. View

16.

Qiu L, Tan E, Zeng L . microRNAs and Neurodegenerative Diseases. Adv Exp Med Biol. 2015; 888:85-105. DOI: 10.1007/978-3-319-22671-2_6. View

17.

Cozzolino M, Rossi S, Mirra A, Carri M . Mitochondrial dynamism and the pathogenesis of Amyotrophic Lateral Sclerosis. Front Cell Neurosci. 2015; 9:31. PMC: 4322717. DOI: 10.3389/fncel.2015.00031. View

18.

Fukunaga K, Shinoda Y, Tagashira H . The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. J Pharmacol Sci. 2015; 127(1):36-41. DOI: 10.1016/j.jphs.2014.12.012. View

19.

Palomo G, Manfredi G . Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control. Brain Res. 2014; 1607:36-46. PMC: 4385426. DOI: 10.1016/j.brainres.2014.09.065. View

20.

Tan W, Pasinelli P, Trotti D . Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim Biophys Acta. 2014; 1842(8):1295-301. PMC: 4074562. DOI: 10.1016/j.bbadis.2014.02.009. View